反応式
[C:1]([C:3]1[CH:4]=[CH:5][C:6]2[O:11][CH2:10][C:9](=[O:12])[N:8]([CH2:13][CH2:14][N:15]3[CH2:20][CH2:19][CH:18]([NH:21][C:22](=[O:28])[O:23][C:24]([CH3:27])([CH3:26])[CH3:25])[CH2:17][CH2:16]3)[C:7]=2[CH:29]=1)#[N:2].I([O-])(=O)(=O)=[O:31].[Na+].COC1C=CC2OCC(=O)N(CCN3CCC(NC(=O)OC(C)(C)C)CC3=O)C=2C=1>O.[Ru](=O)=O.C(Cl)(Cl)Cl>[C:1]([C:3]1[CH:4]=[CH:5][C:6]2[O:11][CH2:10][C:9](=[O:12])[N:8]([CH2:13][CH2:14][N:15]3[CH2:16][CH2:17][CH:18]([NH:21][C:22](=[O:28])[O:23][C:24]([CH3:25])([CH3:26])[CH3:27])[CH2:19][C:20]3=[O:31])[C:7]=2[CH:29]=1)#[N:2]参加物
6
反応物 3
生成物 1
試薬・触媒・溶媒 2
実験手順
tert-Butyl {1-[2-(6-cyano-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethyl]piperidin-4-yl}carbamate (Intermediate 59, 835 mg, 2.1 mmol) was reacted with sodium periodate (2.8 g, 13.1 mmol) and ruthenium (IV) oxide hydrate (30 mg, 20.1 mmol) as described for Intermediate 115 for 16 hours, except, chloroform was used for aqueous workup. The product was obtained as a colorless solid, 230 mg (27%).
後処理
- customThe product was obtained as a colorless solid, 230 mg (27%)
出典と根拠
- ORDレコード
- ord-c1da0a2867c34614ae6b55b865aac30a
- 出典データセット
- uspto-grants-2011_01
- 特許番号
- US07875715B2
関連ノート
読み込み中…